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Objective: Surgical lung volume reduction improves lung function and dyspnea in
advanced emphysema to a variable degree. Because long-term results with this proce-
dure are scant, we prospectively investigated lung function over several years after lung
volume reduction surgery with regard to emphysema morphology.
Methods: Bilateral video-assisted thoracoscopic lung volume reduction surgery was
performed in severely symptomatic patients with marked hyperinflation caused by
advanced nonbullous emphysema. Emphysema heterogeneity was visually graded
on chest computed tomography. Symptoms and lung function were assessed before
the operation and 3, 6, and then every 6 months after the operation.
Results: A total of 115 patients with a median forced expiratory volume in 1 second
of 0.73 L (27% of predicted value) underwent lung volume reduction surgery.
Follow-up extended over a median of 37 months. Median forced expiratory volume
in 1 second significantly increased within 6 months after the operation by 37% in
homogeneous (n  27), by 38% in intermediately heterogeneous (n  37), and by
63% in markedly heterogeneous emphysema (n  51, P  .05 vs other morphol-
ogies). Maximal forced expiratory volume in 1 second was reached within 6 months
after lung volume reduction surgery and decreased in the first postoperative year by
0.16 L per year in homogeneous, by 0.19 L per year in intermediately heterogenous,
and by 0.32 L per year in markedly heterogeneous emphysema (P  .01 vs other
morphologies). The decline in forced expiratory volume in 1 second over subse-
quent years decelerated according to an exponential decay and was similar for all
morphologic types (median annual decrease of 0.09 L [9%]).
Conclusions: Lung volume reduction surgery improves lung function in severe
homogeneous and, to an even greater extent, heterogeneous emphysema. Forced
expiratory volume in 1 second peaks within 6 months postoperatively. The subse-
quent decline is most rapid in the first year and slows down in succeeding years
according to an exponential decay. Therefore, long-term functional results of lung
volume reduction surgery may be more favorable than expected from linear extrap-
olations of short-term observations.
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Several prospective case series1-5 and, morerecently, a few prospective, randomized, con-trolled trials6-8 have demonstrated a relief ofdyspnea and an improvement in lung func-tion, exercise tolerance, and quality of lifeafter lung volume reduction surgery (LVRS)
for emphysema. The amount of improvement is variable
and may depend on various factors, including cause and
morphologic types of emphysema, preoperative lung func-
tion, and amount of resected emphysematous lung tissue.
Certain authors have stressed that patients with distinct
regional differences in tissue destruction (ie, with markedly
heterogeneous emphysema) on computed tomographic (CT)
scanning, perfusion scintigraphy, or both profit most from
LVRS because nonfunctional areas identified by means of
imaging techniques are the ideal targets for resection.9,10 In
previous analyses we corroborated this concept, but more
important, we were able to demonstrate that even patients
with a uniform pattern of emphysematous destruction (ie, a
homogenous type) had significant and clinically relevant
improvement after the operation.11,12 Because data on long-
term outcome after LVRS are scant and have not been
analyzed with regard to the potential effects of emphysema
morphology, we prospectively investigated the initial gain
and the subsequent loss of lung function over several years
after LVRS in patients with various degrees of emphysema
heterogeneity.
Methods
Patients
The patients participated in a prospective trial on the outcome of
LVRS.2 As described previously,13 patients with nonbullous pul-
monary emphysema were included when they were severely symp-
tomatic despite optimal medical therapy, had severe airflow ob-
struction (forced expiratory volume in 1 second [FEV1] of  40%
of predicted value), and had pulmonary hyperinflation (residual
volume [RV] of  200% of predicted value, RV/total lung capac-
ity of  0.60). Severely impaired carbon dioxide diffusing capac-
ity (20% of predicted value) and significant coronary artery
disease represented the major exclusion criteria for the current
study. No systematic rehabilitation was performed at our center
before or after the operation, but the majority of patients had
undergone rehabilitation at other institutions before referral. The
study was approved by the hospital ethics committee, and in-
formed consent was obtained from the patients.
Surgical Intervention
LVRS was performed by means of bilateral, video-assisted, sta-
pled (buttressed or nonbuttressed with bovine pericardium accord-
ing to the protocol of a previous study14) resection of approxi-
mately 30% of lung volume.1 Target areas were identified, by
means of analysis of the CT scans and perfusion scintiscans, as the
lung zones with the most pronounced emphysematous alteration
and the greatest reduction in perfusion. In addition, target areas
were selected on the basis of visual observation of areas with
delayed resorption atelectasis during the surgical intervention.12
Patients were operated on in the supine position if resection in the
upper lobes was planned. For lower lobe resections, patients were
placed in a lateral decubitus position and turned to the other side
after completion of the first side.
Measurements
Clinical evaluation. Spirometry, whole-body plethysmogra-
phy, and measurement of carbon monoxide diffusing capacity
were performed (6200 Autobox; SensorMedics, Yorba Linda,
Calif) according to standard criteria after inhalation of 2 puffs of
albuterol. Arterial blood for blood gas analysis was obtained while
the patient was sitting and breathing room air. Cotinine concen-
tration of the urine was determined as a marker for smoking.15 For
the purpose of the current analysis, a patient was considered a
smoker if his or her urinary cotinine concentration was greater than
1000 mg/L, if greater than 5% of his or her hemoglobin was
saturated with carbon monoxide, or if he or she reported regular
cigarette smoking.
For assessment of the 6-minute walking distance, the patients
walked along the same hospital hallway without supplemental
oxygen. Severity of dyspnea was graded by the American Thoracic
Society modified Medical Research Council (MRC) dyspnea
score, with a scale ranging from 1 to 4.16 Baseline and follow-up
examinations were performed within 1 month before LVRS, at 3
and 6 months after LVRS, and every 6 months thereafter.
Imaging techniques. Preoperative chest CT examina-
tions were performed on a Somatom plus 4 scanner (Sie-
mens, Erlangen, Germany) with a high-resolution technique
by using an increment of 15 mm and a slice thickness of 1
mm at 140 kV and 11 mA. Heterogeneity of emphysema
distribution was graded according to our semiquantitative
staging system, which comprises 3 degrees11:
1. Markedly heterogeneous: a distinct regional difference in
severity of emphysema is present in at least 2 adjacent lung
segments of either lung
2. Intermediately heterogeneous: a distinct regional difference
in severity of emphysema may be present maximally in the
area of one or more than one but not in adjacent segments of
either lung
3. Homogeneous: no regional or only very minor differences in
severity of emphysema are appreciable
Lung perfusion scans were also obtained as a help for identifica-
tion of target areas in cases with homogeneous emphysema distri-
bution on CT scans.12
Data Analysis and Statistics
Summary statistics are presented as medians and quartile ranges
because certain variables were not normally distributed.17 To per-
form statistical comparisons, data were logarithmically trans-
formed to obtain a normal distribution, as confirmed with the
Kolmogorov-Smirnov statistic.18 Changes in variables over time
within and among the 3 groups of patients with different emphy-
sema heterogeneity were evaluated by analysis of variance, fol-
lowed by Newman-Keuls multiple comparisons where appropriate.
Correlation of baseline variables with changes in FEV1 after
LVRS were performed by means of multiple linear regression
analyses.
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In each patient, elapsed time after the operation when the
individual maximal value of FEV1 (FEV1max) was reached was
noted, along with the corresponding gain in FEV1. The maximal
gain was defined as the difference between the maximal minus the
preoperative value of FEV1 and expressed in liters and in percent-
ages of the preoperative value. Graphic display of the individual
time course of FEV1 after FEV1max suggested an exponential
decay. The decrease in FEV1 in the first year after the operation
and the median yearly decrease over subsequent years were deter-
mined to capture this phenomenon numerically. Elapsed time from
the operation to the time when FEV1 had fallen below FEV1max
minus half the maximal gain was also computed. Furthermore, the
decline of FEV1 was modeled by fitting an exponential equation to
the data of each individual patient according to the following
equation:
FEV1 (t)  FEV1max  et/,
where t corresponds to the time elapsed since FEV1max and  to
the time constant of the exponential decay. The half-life of FEV1
expresses the time when FEV1 reaches the value of 0.5 times
FEV1max. It is calculated as follows:
Half-life  ln (0.5/).
Data from individual patients were included only if more than 4
observations were available and if the regression of predicted
versus observed data was statistically significant.
Results
Preoperative Findings
Data of a total of 115 consecutive patients (43 female
patients) were available for analysis. Median patient age at
the time of the operation was 65 years (range, 38-78 years).
Baseline characteristics and follow-up data are summarized
in Table 1. According to the inclusion criteria for the
operation, the patients had severe dyspnea and pronounced
airflow obstruction and hyperinflation preoperatively. In 14
patients PaO2 was less than 55 mm Hg, and in 15 patients
PaCO2 was greater than 45 mm Hg (maximal value, 51 mm
Hg). Six-minute walking distance was limited to 35 to
450 m. Eleven patients had 1-antitrypsin (Pi ZZ) defi-
ciency. Chest CT scoring revealed markedly heterogeneous
emphysema distribution in 51, intermediately heteroge-
neous emphysema distribution in 37, and homogeneous
emphysema distribution in 27 patients. Preoperative FEV1
was greater in the group with markedly heterogeneous em-
TABLE 2. Effect of LVRS on lung function in patients with different emphysema morphology
Before LVRS
3 months
postoperatively
12 months
postoperatively
24 months
postoperatively
48 months
postoperatively
Markedly heterogeneous emphysema
n 51 51 41 35 8
FEV1
L 0.81 (0.64-0.96)§ 1.20 (0.97-1.50)‡ 1.11 (0.82-1.40)‡ 0.96 (0.80-1.25)‡ 1.11 (0.78-1.40)*
% Predicted 27 (21-33) 42 (36-54)‡ 39 (29-48)‡ 35 (29-45)‡ 37 (28-46)*
IVC
L 2.87 (2.24-3.54) 3.73 (3.16-4.37)‡ 3.85 (3.13-4.34)‡ 3.37 (2.86-4.20)* 3.63 (2.59-5.36)
% Predicted 79 (67-90) 98 (86-111)‡ 105 (87-118)‡ 96 (81-110)† 85 (62-114)
RV/TLC 0.66 (0.59-0.71) 0.51 (0.42-0.56)‡ 0.52 (0.44-0.59)‡ 0.54 (0.43-0.62)‡ 0.53 (0.45-0.63)†
Intermediately heterogeneous emphysema
n 37 37 23 14 7
FEV1
L 0.69 (0.56-0.85) 0.97 (0.79-1.15)‡ 0.94 (0.66-1.05)‡ 0.71 (0.61-1.06) 0.74 (0.52-0.87)
% Predicted 26 (24-32) 37 (31-45)‡ 32 (27-45)‡ 32 (25-47)* 31 (25-37)
IVC
L 2.53 (2.02-3.41) 3.03 (2.54-3.97)‡ 3.35 (2.46-4.01)† 2.73 (2.36-3.55) 2.53 (1.72-2.81)
% Predicted 80 (65-86) 97 (82-105)‡ 95 (82-107)‡ 89 (78-97) 85 (71-95)
RV/TLC 0.67 (0.61-0.72) 0.55 (0.51-0.60)‡ 0.57 (0.50-0.61)‡ 0.61 (0.50-0.65) 0.61 (0.56-0.71)
Homogeneous emphysema
n 27 27 20 16 5
FEV1
L 0.67 (0.55-0.75) 0.89 (0.76-1.07)‡ 0.87 (0.70-0.97)‡ 0.79 (0.58-0.94)† 0.83 (0.68-0.87)
% Predicted 25 (23-32) 36 (29-46)‡ 35 (29-40)‡ 31 (28-40)† 29 (27-32)
IVC
L 2.51 (2.10-3.24) 3.07 (2.50-3.58)‡ 2.57 (2.38-3.76)* 2.58 (2.11-3.14)* 2.85 (2.27-3.24)
% Predicted 79 (68-91) 92 (82-102)‡ 91 (80-104)* 84 (76-98) 86 (71-96)
RV/TLC 0.68 (0.64-0.71) 0.56 (0.52-0.59)‡ 0.59 (0.56-0.62)† 0.62 (0.61-0.67) 0.60 (0.57-0.60)
Values are medians (quartile range). IVC, Inspiratory vital capacity; TLC, total lung capacity.
*P  .05; †P  .01; ‡P  .001 for comparison to respective preoperatively value; §P  .05 for comparisons of preoperative values vs. intermediately
heterogeneous and homogeneous, see Table 3 for comparisons among heterogeneity groups at subsequent time points.
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physema distribution (median FEV1, 0.81 L) than in the
other 2 groups (Table 2). However, the medians in FEV1
expressed as a percentage of predicted values (range, 25%-
27%) were not statistically different among groups.
Postoperative Course in the Entire Cohort
Perioperative mortality (within 30 days of the operation)
was 2 (2%) of 115. Postoperative observation extended up
to 78 months (median, 37 months; quartile range, 20-54
months). The loss to follow-up was 5, 9, 12, and 14 patients
at 1, 2, 3, and 4 years after LVRS. In 5 of these patients,
lung transplantation had been performed. The cumulative
numbers of deaths at 1, 2, 3, and 4 years after the operation
were 6, 16, 24, and 28, respectively. Maximal FEV1 after
the operation was achieved within 3 to 6 months. At that
time, the relative decrease in RV (1 - RV after LVRS/RV
before LVRS, an estimate of the reduction of lung volume
in situ19) was 29% (quartile range, 19%-39%).
In Table 1 the course of lung function, walking distance,
and dyspnea is summarized for all patients and grouped
according to the length of postoperative observation. In the
first year after the operation, FEV1 measured in absolute
volume units fell by a median of 0.24 L per year (quartile
range, 0.11-0.43). The median decrease in FEV1 expressed
as a percentage of the individual maximal value was 22%
per year (quartile range, 12%-36%) in the first postoperative
year. Over subsequent years, the median annual decline was
significantly reduced to 0.09 L per year (quartile range,
0.05-0.15 L per year; n  80; P  .00001), corresponding
to a yearly relative loss of FEV1 of 9% per year (quartile
range, 4%-16% per year; n  80; P  .0005 vs first year
values). After a median duration of 12 months after the
operation (quartile range, 9-24 months; n  100 patients),
half of the gain of FEV1 was lost (ie, FEV1 had fallen from
FEV1max to below the value of FEV1max minus half the
maximal gain).
In 60 patients in whom an exponential function could be
fitted to the decay in FEV1, there was a close match of
predicted value with observed data (median coefficients of
determination r 2  0.88; quartile range, 0.82-0.95; P 
.05). Figure 1 shows the changes in FEV1 over the individ-
ual times of follow-up. The estimated time for FEV1 to fall
back to the preoperative value was 38 months (quartile
range, 21-64 months; Figures 1 and 2). The half-life of
FEV1 (ie, the time required for FEV1 to fall to 50% of its
initial maximal value) was estimated at 63 months (quartile
range, 45-87; Figure 2). Neither resumption of smoking
after the operation (documented in 14 patients at any time
during their follow-up) nor 1-antitrypsin deficiency
(present in 11 patients) had a statistically significant effect
on the decline in FEV1 after the operation, as assessed by
the measures mentioned above.
Postoperative Course According to CT Morphology
In Table 2 data are presented according to CT morphologic
emphysema heterogeneity. The loss of follow-up was not
statistically different among the 3 groups. The relative de-
crease in RV (1 - RV after LVRS/RV before LVRS) was
32% (quartile range, 23%-42%) in the group with markedly
heterogeneous emphysema, 28% (quartile range, 19%-39%)
in the group with intermediately heterogeneous emphy-
sema, and 22% (quartile range, 19%-31%; P  .5 vs mark-
edly heterogeneous) in the group with homogeneous em-
physema. The functional gain was greatest in the group with
markedly heterogeneous emphysema, but in patients with
intermediately heterogeneous and homogeneous emphy-
sema, significant functional and symptomatic improvements
were also achieved (Table 2).
Figure 1 provides a graphic display of the initial gain and
subsequent loss of FEV1 in the 3 groups of patients with
different emphysema morphologic patterns. The absolute
and relative gain in FEV1 (in liters and in percentage of
preoperative value, respectively) was greatest in markedly
heterogeneous emphysema. There was a trend for a greater
subsequent loss of FEV1 (in absolute volume units [ie,
liters]) in markedly heterogeneous emphysema during the
first and subsequent years compared with intermediately
heterogeneous or homogeneous emphysema. However, nei-
ther the time until 50% of the individual gain was lost nor
the relative decline (in percentage) over the first and sub-
sequent years nor the half-life of FEV1 differed among
groups of patients with different emphysema morphologic
patterns (Table 3, Figures 1 and 2).
The baseline values and follow-up values at 3, 12, 24, 36,
and 48 months after LVRS for diffusing capacity, blood
gases (PaO2 and PaCO2), 6-minute walking distance, and
MRC dyspnea scores did not statistically differ among the 3
groups with different emphysema morphologic patterns,
and the values are listed for the entire cohort in Table 1.
Data for the groups with different emphysema heterogeneity
are therefore not shown.
Discussion
We prospectively studied mortality and functional and
symptomatic improvement over several years after bilateral
videothoracoscopic LVRS. The major improvement in air-
flow obstruction and hyperinflation achieved with LVRS
was associated with significant relief of dyspnea and im-
proved walking distance. The relatively long follow-up pe-
riod (median, 37 months) allowed us to demonstrate for the
first time that FEV1, after reaching its peak at 3 to 6 months
after the operation, follows an exponential decay. Our anal-
ysis helps to better understand the evolution of lung func-
tion after LVRS by providing data on both the initial gain
and the subsequent loss of FEV1 in emphysema of various
degrees of heterogeneity (Figure 2).
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Figure 1. Left panels, The initial gain of individual FEV1 in 60 patients is represented by lines connecting observed
values before LVRS (plotted at time 0 months) with maximal values attained at 3 to 6 months after the operation.
Right panels, The subsequent decline in FEV1 closely follows individually fitted exponential functions. These are
represented by lines of a length corresponding to the individual elapsed time since FEV1 started to decline from
its maximal value (time 0 months after LVRS). Because of a certain degree of imprecision in the prediction
equations, maximal measured FEV1 values (left panels) do not always coincide with the corresponding individual
values at the beginning of the exponential decay (right panels). The upper, middle, and lower panels reflect the
time course of FEV1 in patients with different emphysema morphologic patterns.
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Short-term Results After LVRS
The short-term outcome achieved in the current study com-
pares favorably with results achieved in other centers. With
a value of less than 2%, the perioperative mortality was at
the lower end of the range of 0%20 to 6% to 17%8 reported
by others. Dyspnea decreased in all patients by at least 2
Figure 2. The layout of the figure is similar to that of Figure 1. On the left side, the panels represent the medians
of measured gains in FEV1 for patients with markedly heterogeneous, intermediately heterogeneous, and homo-
geneous emphysema distribution. The right panels represent the exponential decay functions of FEV1 with origins
and time constants corresponding to respective median values of the different heterogeneity groups. As explained
in the legend for Figure 1, for individuals, the measured medians of maximal FEV1 are not identical with the
estimated beginning of the exponential decay. In the top panels FEV1 is expressed in absolute volume units (in
liters). In the bottom panels FEV1 is expressed as a percentage of individual preoperative baseline values to
provide an impression of relative changes over time. Although the absolute and relative gain in FEV1 is greater in
patients with markedly heterogeneous emphysema than in the other 2 groups, the subsequent decline expressed
in relative volume units (in percentages) is similar for the 3 groups (P  not significant).
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points on the MRC scale. In the entire cohort of 115 patients
(Table 1), the significant reduction of lung volume, reflected
by the 29% median decrease in RV,19 was associated with a
median gain in FEV1 of 43%. This is similar to the mean
increase in FEV1 of 51% reported for 150 patients by
Cooper and colleagues.3 In our 51 patients with markedly
heterogeneous emphysema, FEV1 increased even more (ie,
by 63%; Table 3), which is close to the mean increase in
FEV1 of 60% in 90 patients with heterogeneous emphysema
treated with bilateral videothoracoscopic LVRS by Brenner
and coworkers.4 In the 2 randomized studies for which the
relative gain in FEV1 was reported, the corresponding val-
ues were less than 30%20 and 53%,7 respectively.
We were able to further substantiate our previous find-
ings of a significant and clinically relevant functional and
symptomatic benefit from LVRS in a larger number of
patients with completely diffuse, homogenous emphysema
followed over longer time periods than in the earlier re-
ports.11,12 The significant differences in short-term outcome
among groups of patients classified according to emphy-
sema heterogeneity by means of visually scoring the chest
CT illustrates the clinical relevance of our simple grading
system11 and underlines an effect of morphologic factors on
the success of LVRS. Nevertheless, the association of em-
physema heterogeneity with favorable functional outcome
is relatively modest and may, in part, be related to a greater
extent of resection by the surgeon in heterogeneous emphy-
sema, if target areas are clearly visualized on the CT.
Evolution of Symptoms and Function Over Several
Years
Our data suggest that dyspnea is persistently relieved after
LVRS in the majority of patients over at least 48 months
(Table 1). Median walking distance also remained increased
above preoperative levels over this time period. On the other
hand, airflow obstruction and hyperinflation began to dete-
riorate after maximal improvement within 3 to 6 months
after the operation. Within the first year after LVRS, the
median loss of FEV1 in our entire cohort (n  91 patients
followed up over the first year) was 0.24 L. This is consis-
TABLE 3. Changes in FEV1 with LVRS according to emphysema morphology
Markedly
heterogeneous
emphysema
Intermediately
heterogeneous
emphysema
Homogeneous
emphysema
FEV1 n
Median
(quartile range) n
Median
(quartile range) n
Median
(quartile range)
Preoperative value
L 51 0.81 (0.64-0.96)* 37 0.69 (0.56-0.85) 27 0.67 (0.55-0.75)
% predicted 27 (21-33) 26 (24-32) 25 (23-33)
Maximal value after LVRS
L 51 1.24 (1.04-1.61)§ 37 0.97 (0.79-1.19) 27 0.92 (0.78-1.13)
Maximal gain relative to
preoperative value
L 51 0.48 (0.27-0.68)§ 37 0.23 (0.14-0.42) 27 0.26 (0.18-0.39)
% Baseline 63 (33-98)* 38 (20-62) 37 (26-57)
Measured time after LVRS until
gain was reduced to half of
initial maximal value, mo
46 18 (12-24) 31 12 (6-24) 23 18 (12-30)
Measured decrease from maximal
value during first year after LVRS
L 43 0.32 (0.19-0.45)‡ 25 0.19 (0.09-0.45) 23 0.16 (0.08-0.35)
% 26 (15-36) 22 (12-37) 15 (11-36)
Measured yearly decrease in the
second and subsequent years
after LVRS
L/y 39 0.12 (0.07-0.17)*§ 22 0.06§ (0.02-0.11) 19 0.08§ (0.3-0.15)
%/y 11 (6-15)§ 5§ (2-11) 8 (2-18)
Estimated half-life of exponential
decay, mo
32 53 (45-77) 14 86 (50-116) 14 66 (41-99)
The number of cases (n) for certain variables is less than that for preoperative values since certain patients were followed for less than 1 year after LVRS
(n  24/115), because reduction of gain in FEV1 did not fall below half of initial value (n  15/115), or because exponential fit to observed postoperative
FEV1 was not statistically significant (n  9/13 patients with 4 follow-up observations, n  11/67 patients with 4 follow-up observations).
*P  .05, †P  .01, and ‡P  .05 versus intermediately heterogeneous and homogeneous.
§P  .02 for comparison of decrease versus first year within same group.
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tent with a previous report4 of a mean decline in FEV1 of
0.255 L per year (n  90 patients, mean follow-up of 420
days after the operation). Because this result4 reflects the
slope of the linear regression of FEV1 versus time in pa-
tients with a mean follow-up that was close to 1 year, the
resulting mean loss of FEV1 is comparable with the de-
crease in FEV1 documented in the first year in our cohort
(Table 3).
Observation of changes in lung function over several
years suggested a nonlinear course (Table 1). This was
analyzed in greater detail for FEV1, which declined much
more rapidly in the first than in subsequent years after
LVRS (ie, group medians of the fall were between 0.16 and
0.32 L per year initially and between 0.06 and 0.12 L per
year in the later course; P  .0005 vs fall in the first year;
Table 3). This indicates that long-term trends in FEV1 after
LVRS can not be derived by means of linear extrapolation
of the early postoperative course. Instead, graphic represen-
tation and statistical analysis confirmed an exponential de-
cay (Figures 1 and 2). In an individual patient FEV1 closely
followed the course predicted by the following general
equation:
FEV1 (at a given time [t] after the peak value)
Maximal postoperative FEV1  e-t/individual time constant
A median of 88% in the variability of FEV1 could be
explained accordingly, suggesting that the exponential func-
tion may provide a useful guide in the assessment and
counseling of patients after LVRS. It is conceivable that our
exponential model, which is different from the linear poly-
nomial equation applied to describe the effects of smoking
cessation and inhalation therapy on the course of FEV1,21
performed well in capturing the much more striking effect
of a surgical intervention such as LVRS.
Interestingly, the characteristics of exponential decay in
FEV1, such as the observed time to half the initial gain in
FEV1 (measured in 100 of 115 patients, Table 3) or the
estimated half-life of FEV1 (computed for 60 patients) did
not statistically differ among the 3 groups with different
emphysema morphologic patterns (Figure 2). Because the
exponential decay was fitted to data of patients with a
follow-up of at least 21 months after the maximal postop-
erative FEV1 only (ie, postoperative observation 2 years
after LVRS) and because of mortality (16/115 patients at 2
years after LVRS) and losses to follow-up (9/115 patients at
2 years), the subgroup of 60 patients in whom this analysis
could be performed may reflect a certain bias toward a more
favorable course and, obviously, is representative for survi-
vors over this time period only. Nevertheless, the prediction
derived from 60 patients together with the time until half of
the gain in FEV1 was lost (measured in 100 patients) may
still be typical for the time course of the decay in FEV1 in
many patients who undergo LVRS.
Conclusions
We confirmed that heterogeneity of emphysema distribution
graded visually on the chest CT correlates with the degree
of functional improvement in the first few months after
LVRS. The early rate of decline in FEV1 from the maximal
value in the first year after the operation was significantly
greater than that in subsequent years, according to an ex-
ponential decay. Therefore, our data, obtained in a fairly
large number of patients over several years, illustrate that
the course of lung function in intermediate and long-term
survivors of LVRS may be more favorable than previously
expected from linear extrapolations of short-term observa-
tions.
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Discussion
Dr Joel Cooper (St Louis, Mo). I congratulate Dr Weder and
his colleagues on an outstanding series and terrific results in a
difficult group of patients.
Dr Weder’s report confirms the long-term benefit produced by
LVRS and suggests that maybe the restrictive selection criteria we
have adhered to in the past might be somewhat relaxed. Because
LVRS is a palliative procedure and because emphysema is an
unrelenting and progressive disease, much of the controversy
surrounding LVRS centers on how much benefit is produced, how
long it lasts, and for which patients the magnitude and the duration
of benefit justifies the risk to the patient and the cost to the payer.
On the basis of short-term data, others have suggested that the
rate of decline in lung function after LVRS might somehow be
accelerated, but Dr Weder’s thoughtful analysis demonstrates that
the benefit persists for years. This is consistent with our own recent
analysis of 5 years’ follow-up on our first 200 patients, showing
that, on average, the benefit persists for 5 years or more and that it
takes at least 3 years for half of the improvement in the FEV1 to
be lost.
Dr Weder’s results have again confirmed that the patients with
a heterogeneous pattern of destruction benefit the most from
LVRS, but his analysis suggests that the loss of benefit follows a
similar logarithmic decay for each of the 3 different morphologic
patterns he has identified.
I have 3 questions.
The first relates to your selection process. In your manuscript
you noted that you had 51 patients with a more ideal heteroge-
neous pattern, and 27 patients in this series had the more diffuse
homogeneous pattern, and yet we see 3 or 4 patients with a
homogeneous pattern for every one we see with a more favorable
pattern. How do you select among those patients, and specifically,
because the morphologic patterns that you have demonstrated are
based on regional differences and not absolute severity, do you
tend to shy away from the patients with homogeneous severe
destruction?
The second and third questions relate to the results. In all
patients LVRS produces improved mechanics by reducing hyper-
inflation, and this is reflected in a reduction in RV and an improve-
ment in the FEV1. But in patients with heterogeneous disease, it
may also improve gas exchange by redistributing ventilation, and
this is reflected in the improvement in PO2 and the reduction in
oxygen requirements. Did you, in your series, see less benefit in
terms of gas exchange improvement in the patients with a homo-
geneous pattern?
Finally, your analysis and that of most of us is focused primar-
ily on the FEV1, but I increasingly believe that the long-term
benefits of volume reduction may have more to do with a reduction
in the hyperinflation, as reflected in the RV, than it does with the
improvement in the FEV1. Have you any thoughts on that matter
or have you analyzed the follow-up in RV in a similar fashion?
Dr Weder. Thank you very much for these 3 questions. The
first question concerns the selection of patients with more homo-
geneous disease and whether we are more selective in picking
them. We select patients with no distinct target areas for resection
only if all selection criteria are fulfilled. We are especially strict in
excluding patients with a very low functional reserve—expressed
by carbon monoxide diffusion capacity below 20% predicted or an
FEV1 below 20% predicted. Additionally, the information from
the visual analysis of the CT scan is included. Unfortunately, the
radiologic criteria of a too destroyed and almost vanished lung are
not defined with respect to lung volume reduction surgery. There-
fore, some patients might also be excluded from surgery based on
the clinical judgment of a radiologically too destroyed lung.
The second point concerns changes in gas exchange with
regard to the morphology. You suspect that patients with markedly
heterogeneous emphysema show much more improvement in
terms of gas exchange. In fact, we found a trend of more improve-
ment only in heterogeneous disease but no significant difference
between the 3 morphologic groups.
The last question regards the measurement of FEV1 as the best
indicator for qualifying this procedure. Again, many of us have
observed patients who claimed a clear benefit from this procedure
without having a great change in FEV1 and the only improved
parameter being a reduction in hyperinflation. However, most
groups, including us, would like to see an improvement in FEV1,
since this parameter is most widely used to validate lung function.
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